Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias

J Inherit Metab Dis. 2008 Feb;31(1):67-72. doi: 10.1007/s10545-007-0572-4. Epub 2008 Jan 22.

Abstract

Background: A significant percentage of patients with hyperphenylalaninaemia (HPA) due to primary deficiency of the phenylalanine hydroxylase enzyme (PAH) respond to a dose of tetrahydrobiopterin (BH(4)) with an increased rate of phenylalanine (Phe) disposal. The effect is exploited therapeutically, with some patients on BH(4) even tolerating a normal diet.

Aim: Classification of the Phe blood level response to a BH(4) load by percentage reduction (PR) suffers from loss of information: only part of usually more extensive test data is used, and PR values for different times after load cannot be compared directly. Calculation of half-life (t (1/2)) of blood Phe is proposed as an alternative. This classic measure unifies interpretation of tests of different duration (e.g. 8 or 15 h). t (1/2) subsumes first-order formation of tyrosine, of Phe metabolites, and renal Phe excretion; zero-order net protein synthesis can be neglected during short-time tests.

Method: t (1/2) is easily and robustly obtained by fit-ting the total set of (3-4) data points to a log-linear regression.

Results: The advantage of calculating t (1/2) is exemplified by the analysis of selected published data. The results clearly speak in favour of an 8 h test period because so-called 'slow' responders could also be detected within this time window and because tests of longer duration are less reliable kinetically. Sequential Phe and Phe/BH(4) loading tests appear advantageous because the 'natural' t (1/2) (without supplementation of BH(4)) is not normally known beforehand.

Conclusion: With t (1/2) as a reliable parameter of BH(4) responsiveness, therapeutic decisions would be more rational and genotype-phenotype analysis may also profit.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Biopterins / administration & dosage
  • Biopterins / analogs & derivatives*
  • Biopterins / pharmacokinetics
  • Diagnostic Techniques and Procedures
  • Half-Life
  • Humans
  • Infant, Newborn
  • Models, Theoretical
  • Phenylalanine / blood*
  • Phenylalanine / metabolism
  • Phenylalanine Hydroxylase / metabolism
  • Phenylketonurias / classification*
  • Phenylketonurias / diagnosis*
  • Phenylketonurias / drug therapy
  • Time Factors

Substances

  • Biopterins
  • Phenylalanine
  • Phenylalanine Hydroxylase
  • sapropterin